Tulane starts a prospective trial of XM-ONE® in Kidney Transplantation.

Tulane University Hospital, New Orleans, LA, USA will in May start a prospective trial in Kidney Transplantation investigating the potential of cross match XM-ONE® as part of the risk assessment of their patients.

It is our belief that patients at higher risk for rejection can be identified using XM-ONE® technology” says Professor Joseph Buell, chief of surgery at Tulane. “Earlier identification of at risk patients prior to a clinically relevant rejection will allow us to modify our surveillance program and immunosuppression. In order to evaluate the potential of this test within our traditionally challenging population we started a baseline evaluation of XM-ONE®”, he continues.

The study at Tulane will include 50 contiguous Caucasian and 50 contiguous African American renal transplant recipients and the patients will be tested with XM-ONE® both before transplantation and at a follow-up 6 months post transplantation.

This is clearly encouraging for us”, says Anders Karlsson, CEO of Allenex. “It further strengthens our belief that XM-ONE® has a role in the pre transplant risk assessment. The initiative of Prof. Buell and the transplant team at Tulane to also include post-transplant evaluation to the repertoire makes this even more exciting”, he ends.

About Tulane University
Traditionally Tulane University has cared for a challenging end stage renal failure population. The program currently performs 100 renal transplants a year, with African American population in excess of 65%. Tulane recipients are often at increased immunologic risk; namely a high PRA (>30) 20% and re transplants (about 10%). In their patient population they have identified a significantly higher incidence of rejection and antibody mediated rejection.

For more information please contact:

Anders Karlsson, CEO Allenex AB, tel: +4670-918 0010, e-mail: anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act And/or the Financial Instruments Trading Act. The information was submitted for publication on May 28, 2012, at 11.00 CET.

Allenex is a life science-company that develop, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.

About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.


Documents & Links